Clozapine metabolism rate as a possible index of drug-induced granulocytopenia

M. C. Mauri, R. Rudelli, S. Bravin, S. Gianetti, E. Giuliani, A. Guerrini, R. Orlandi, G. Invernizzi

Research output: Contribution to journalArticlepeer-review


A possible relationship between haematological adverse reactions and clozapine (CLZ) metabolism rate was studied. Sixteen chronic schizophrenic outpatients (mean age 34.62 years ± 7.56 SD) were treated with CLZ, 75-600 mg/daily for 9 weeks. CLZ and norclozapine (NCLZ) plasma levels were determined weekly, contemporarily with blood cell counts. CLZ plasma levels ranged from 25 to 1270 ng/ml (mean 266.27 ng/ml ± 197.44 SD), while NCLZ plasma levels ranged from 25 to 1280 ng/ml (mean 169.0 ng/ml ± 127.94 SD). NCLZ/CLZ ratio ranged from 0.13 to 1.72 (mean 0.72 ± 0.28 SD). Leukocyte count ranged from 5.2 to 18.8 109/1 (mean 9.37 109/1 ± 2.94 SD) and neutrophil count ranged from 1.8 to 13.4 109/l (mean 5.73 ± 2.57 SD). No correlation was found between CLZ dosage and NCLZ plasma levels. Both CLZ and NCLZ plasma levels correlated positively with neutrophil count (CLZ: P = 0.001, r = 0.26; NCLZ: P = 0.01, r = 0.20). The correlation between NCLZ/CLZ plasma level ratio and neutrophil count was significantly negative (P = 0.002, r = 0.25). These preliminary data suggest that the NCLZ/CLZ ratio, as an index of CLZ metabolism, might be a possible risk factor associated with CLZ treatment.

Original languageEnglish
Pages (from-to)341-344
Number of pages4
Issue number4
Publication statusPublished - 1998


  • Clozapine
  • Granulocytopenia
  • Metabolism

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Clozapine metabolism rate as a possible index of drug-induced granulocytopenia'. Together they form a unique fingerprint.

Cite this